Critical Comparison: Mangoceuticals (MGRX) vs. Its Competitors

Mangoceuticals (NASDAQ:MGRXGet Free Report) is one of 18 public companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it contrast to its competitors? We will compare Mangoceuticals to related businesses based on the strength of its risk, dividends, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Mangoceuticals and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mangoceuticals 0 0 0 0 N/A
Mangoceuticals Competitors 36 288 416 146 2.76

As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 14.55%. Given Mangoceuticals’ competitors higher possible upside, analysts plainly believe Mangoceuticals has less favorable growth aspects than its competitors.

Profitability

This table compares Mangoceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mangoceuticals -1,053.93% -243.34% -200.73%
Mangoceuticals Competitors -816.62% -48.14% -36.60%

Earnings & Valuation

This table compares Mangoceuticals and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Mangoceuticals $866,792.00 -$9.21 million -0.41
Mangoceuticals Competitors $2.39 billion $82.32 million 13.62

Mangoceuticals’ competitors have higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Mangoceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, Mangoceuticals’ competitors have a beta of 3.97, suggesting that their average share price is 297% more volatile than the S&P 500.

Institutional and Insider Ownership

56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 61.8% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by institutional investors. 39.3% of Mangoceuticals shares are owned by insiders. Comparatively, 27.3% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Mangoceuticals competitors beat Mangoceuticals on 9 of the 10 factors compared.

Mangoceuticals Company Profile

(Get Free Report)

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.